☰

cached image

Richard F. Borch, M.D., Ph.D. - Publications

Affiliations: 
Purdue University, West Lafayette, IN, United States 
Area:
Anticancer Drugs: Design, Synthesis, and Mechanisms of Action
Website:
http://www.mcmp.purdue.edu/faculty/?uid=rickb
Tree Info Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Huang R, Oh H, Arrendale A, Martin VA, Galan J, Workman EJ, Stout JR, Walczak CE, Tao WA, Borch RF, Geahlen RL. Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochemical Pharmacology. 86: 597-611. PMID 23830822 DOI: 10.1016/J.Bcp.2013.06.024  0.468
2012 Arrendale A, Kim K, Choi JY, Li W, Geahlen RL, Borch RF. Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity. Chemistry & Biology. 19: 764-71. PMID 22726690 DOI: 10.1016/J.Chembiol.2012.05.011  0.405
2011 Marian C, Huang R, Borch RF. Design and synthesis of a potential SH2 domain inhibitor bearing a stereodiversified 1,4-cis-enediol scaffold. Tetrahedron. 67: 10216-10221. PMID 22199405 DOI: 10.1016/J.Tet.2011.10.014  0.635
2011 Kelley MR, Luo M, Reed A, Su D, Delaplane S, Borch RF, Nyland RL, Gross ML, Georgiadis MM. Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxidants & Redox Signaling. 14: 1387-401. PMID 20874257 DOI: 10.1089/Ars.2010.3410  0.711
2011 Arrendale AA, Huang R, Geahlen R, Borch R. Abstract B184: Design, synthesis, and evaluation of novel mitotic centromere-associated kinesin (MCAK) inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B184  0.547
2011 Arrendale AA, Kim K, Geahlen R, Borch RF. Abstract A124: Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A124  0.442
2010 Nyland RL, Luo M, Kelley MR, Borch RF. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1). Journal of Medicinal Chemistry. 53: 1200-10. PMID 20067291 DOI: 10.1021/Jm9014857  0.715
2008 Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, Nyland RL, Borch RF, Qiao X, Georgiadis MM, Kelley MR. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxidants & Redox Signaling. 10: 1853-67. PMID 18627350 DOI: 10.1089/Ars.2008.2120  0.689
2006 Wu W, Borch RF. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs. Molecular Pharmaceutics. 3: 451-6. PMID 16889439 DOI: 10.1021/Mp060006G  0.361
2006 Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ, Mattingly RR. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. Biochemical Pharmacology. 72: 1485-92. PMID 16797490 DOI: 10.1016/J.Bcp.2006.04.010  0.303
2006 Garrido-Hernandez H, Moon KD, Geahlen RL, Borch RF. Design and synthesis of phosphotyrosine peptidomimetic prodrugs. Journal of Medicinal Chemistry. 49: 3368-76. PMID 16722656 DOI: 10.1021/Jm060142P  0.418
2004 Tobias SC, Borch RF. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Molecular Pharmaceutics. 1: 112-6. PMID 15832507 DOI: 10.1021/Mp034019V  0.367
2004 Wu W, Freel Meyers CL, Borch RF. A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. Organic Letters. 6: 2257-60. PMID 15200334 DOI: 10.1021/Ol049267J  0.747
2003 Freel Meyers CL, Borch RF. Novel method for the immobilization of nucleotides. Organic Letters. 5: 341-4. PMID 12556187 DOI: 10.1021/Ol0273607  0.732
2003 Hernick M, Borch RF. Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs. Journal of Medicinal Chemistry. 46: 148-54. PMID 12502368 DOI: 10.1021/Jm0203229  0.723
2002 Hernick M, Flader C, Borch RF. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. Journal of Medicinal Chemistry. 45: 3540-8. PMID 12139465 DOI: 10.1021/Jm020191B  0.725
2001 Tobias SC, Borch RF. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. Journal of Medicinal Chemistry. 44: 4475-80. PMID 11728193 DOI: 10.1021/jm010337r  0.308
2001 Borch RF, Liu J, Joswig C, Baggs RB, Dexter DL, Mangold GL. Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. Journal of Medicinal Chemistry. 44: 74-7. PMID 11141090 DOI: 10.1021/Jm000359Y  0.315
2001 Steinberg G, Borch RF. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. Journal of Medicinal Chemistry. 44: 69-73. PMID 11141089 DOI: 10.1021/Jm000306G  0.373
2000 Freel Meyers CL, Borch RF. Activation mechanisms of nucleoside phosphoramidate prodrugs. Journal of Medicinal Chemistry. 43: 4319-27. PMID 11063626 DOI: 10.1021/Jm000302B  0.325
2000 Freel Meyers CL, Hong L, Joswig C, Borch RF. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs. Journal of Medicinal Chemistry. 43: 4313-8. PMID 11063625 DOI: 10.1021/Jm000301J  0.434
2000 Flader C, Liu J, Borch RF. Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. Journal of Medicinal Chemistry. 43: 3157-67. PMID 10956224 DOI: 10.1021/Jm000179O  0.4
2000 Borch RF, Liu J, Schmidt JP, Marakovits JT, Joswig C, Gipp JJ, Mulcahy RT. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. Journal of Medicinal Chemistry. 43: 2258-65. PMID 10841804 DOI: 10.1021/Jm0001020  0.339
1995 Fries KM, Joswig C, Borch RF. Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs. Journal of Medicinal Chemistry. 38: 2672-80. PMID 7629806 DOI: 10.1021/Jm00014A019  0.45
1991 Borch RF, Valente RR. Synthesis, activation, and cytotoxicity of aldophosphamide analogues. Journal of Medicinal Chemistry. 34: 3052-8. PMID 1920356 DOI: 10.1021/Jm00114A014  0.392
1991 Borch RF, Canute GW. Synthesis and antitumor properties of activated cyclophosphamide analogues. Journal of Medicinal Chemistry. 34: 3044-52. PMID 1920355 DOI: 10.1021/Jm00114A013  0.385
1990 Montine TJ, Borch RF. Role of endogenous sulfur-containing nucleophiles in an in vitro model of cis-diamminedichloroplatinum(II)-induced nephrotoxicity. Biochemical Pharmacology. 39: 1751-7. PMID 2344372 DOI: 10.1016/0006-2952(90)90121-Z  0.516
1990 Borch RF, Montine TJ. Renal toxicity of antineoplastic agents. Toxicology Letters. 53: 93-6. PMID 2219193 DOI: 10.1016/0378-4274(90)90100-Z  0.452
1988 Qazi R, Chang AY, Borch RF, Montine T, Dedon P, Loughner J, Bennett JM. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. Journal of the National Cancer Institute. 80: 1486-8. PMID 2846857 DOI: 10.1093/Jnci/80.18.1486  0.509
1987 Borch RF, Millard JA. The mechanism of activation of 4-hydroxycyclophosphamide. Journal of Medicinal Chemistry. 30: 427-31. PMID 3806624 DOI: 10.1021/Jm00385A029  0.316
1987 Dedon PC, Borch RF. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochemical Pharmacology. 36: 1955-64. PMID 2954556 DOI: 10.1016/0006-2952(87)90494-1  0.568
1986 Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Research. 46: 2751-5. PMID 3009000  0.47
1986 Bodenner DL, Dedon PC, Keng PC, Borch RF. Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition. Cancer Research. 46: 2745-50. PMID 2870800  0.523
1984 Borch RF, Hoye TR, Swanson TA. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution. Journal of Medicinal Chemistry. 27: 490-4. PMID 6708051 DOI: 10.1021/Jm00370A010  0.305
1977 Borch RF, Evans AJ, Wade JJ. Synthesis of 8-epi-dendrobine. Journal of the American Chemical Society. 99: 1612-9. PMID 839010 DOI: 10.1002/Chin.197721313  0.309
1973 Borch RF, Newell RG. A novel synthesis of 2-oxo-1,2,3,4-tetrahydrocarbazoles Journal of Organic Chemistry. 38: 2729-2730. DOI: 10.1021/Jo00955A039  0.347
1972 Borch RF, Grudzinskas CV, Peterson DA, Weber LD. A new synthesis of substituted 2(1H)-pyridones. Synthesis of a potential camptothecin intermediate Journal of Organic Chemistry. 37: 1141-1145. DOI: 10.1021/Jo00973A015  0.318
1964 Stork G, Borch R. A Synthesis ofcis-Jasmone Journal of the American Chemical Society. 86: 936-937. DOI: 10.1021/Ja01059A047  0.512
1964 Stork G, Borch R. A New Synthesis of 1,4- and 1,5-Diketones Journal of the American Chemical Society. 86: 935-936. DOI: 10.1021/Ja01059A046  0.505
Show low-probability matches.